��������

Matthieu Delincé is currently the Director and Head of Oncology Research at Memo Therapeutics AG. Prior to this role, Matthieu has held various positions in companies such as HiFiBiO Therapeutics, Harvard University, and Boston Children's Hospital. With a background in Bioengineering, Matthieu has a strong research profile, with experience in antibody discovery, cell line development, and host-pathogen interactions. Matthieu's expertise in microfluidics has led to advancements in oncology and infectious diseases research.